Marine derived compounds have been explored and considered as possible antitumor agents. In this study we analyzed extracts of the sponge Cribrochalina vasculum for their ability to inhibit tumor cell proliferation. Screening identified two acetylenic compounds of similar structure that showed strong tumor specific toxicity in non small cell lung carcinoma (NSCLC) cells and small cell lung carcinoma cells, less prominent toxicity in ovarian carcinoma while having no effect on normal cells. These acetylenic compounds were found to cause a time dependent increase in activation of apoptotic signaling involving cleavage of caspase-9, caspase-3 and PARP, as well as apoptotic cell morphology in NSCLC cells, but not in normal fibroblasts. Further analysis demonstrated that these compounds caused conformational change in Bak and Bax, resulted in loss of mitochondrial potential and cytochrome c release in NSCLC cells. Moreover, a decreased phosphorylation of the growth factor signaling kinases Akt, mTOR and ERK was evident and an increased phosphorylation of JNK was observed. Thus these acetylenic compounds hold potential as novel therapeutic agents that should be further explored for NSCLC and other tumor malignancies.
Introduction
Marine organisms have been shown to be a great source of pharmaceutical compounds which can be used for anticancer, antiviral or anti-inflammatory purposes. Since the 1970´s there is a steady increase in the number of new compounds discovered and the number of registered patents is also growing (1) (2) (3) . Among the different marine organisms, sponges (Porifera) have been identified as the most promising source of new compounds with anticancer potential (2) (3) (4) (5) . The leading role of Porifera as a source of new anti-cancer compounds is likely attributed to their long evolutionary history, extreme plasticity and their remarkably rich associated microbiota (4) . Indeed many sponge-derived compounds are at different stages of development (preclinical to phase III and preregistration) and also to some extent in clinical use (6, 7) . Successful examples are discodermolide, trabectedin, cytosar-U and eribulin (8) (9) (10) (11) . Cytosar-U more commonly known as Ara-C, identified in Cryptotethia crypta, is clinically approved for the treatment of acute myeloid leukemia (12) .
Another example is Eribulin, a truncated analogue of the natural product halichondrin-B isolated from the sponge Halichondria okadai. This agent was approved by the U.S. Food and Drug Administration in 2010, to treat patients with metastatic breast cancer (11) . Trabectedin is yet another example of a compound from the marine source, the Caribbean marine tunicate Ecteinascidia turbinata, which has passed all steps of development into a pharmaceutical agent and is approved for cancer patients with advanced or metastatic soft-tissue sarcoma or ovarian carcinoma (10) .
For non-small cell lung carcinoma (NSCLC), small cell lung carcinoma (SCLC) as well as ovarian carcinoma prognosis is generally poor which in part is explained by the fact that these tumor cells are highly resistant to known chemotherapeutic agents used in the disseminated stage of these diseases. For all these tumor entities failure to elicit apoptotic response as well as increased growth factor signaling both contributes to the chemotherapy refractory phenotype (13, 14) . Hence novel agents, which can circumvent these signaling aberrations, are needed.
In the course of our screening for anti-tumor agent from marine sponges, (3S)-icos-4E-en-1-yn-3-ol (1) and (3S)-14-methyldocos-4E-en-1-yn-3-ol (2) were isolated from Caribbean sponge Cribrochalina vasculum (family Niphatidae, order Haplosclerida). Structure elucidation and literature search of these compounds revealed that they both were previously described (15) (16) (17) and reported to have anti-tumor activity, yet their mechanism of action for induction of tumor cell death has not been described. Beside these compounds, several other related acetylenic alcohols have been previously reported from the sponge C. vasculum. Such related acetylenic alcohols were shown to exhibit immunosuppressive activity, toxicity toward brine shrimp and also to possess antitumor activity (8, 15, 18, 19) . Here we show that compound 1 causes strong cytotoxic activity in tumor cells from NSCLC, SCLC and ovarian carcinoma but not in normal cell lines and primary cells tested. Yet we see differences also among the tumor cells with NSCLC being more sensitive than SCLC and ovarian carcinoma. For compound 2 a cytotoxic effect was evident in NSCLC and SCLC whereas in ovarian carcinoma the difference compared to normal cells was less prominent.
Nevertheless, in NSCLC we can demonstrate that both these compounds, isolated from sponge C. vasculum, activate intrinsic apoptotic signaling cascades i.e. activation of Bak/Bax, decreased phosphorylation of Bad, depolarization of mitochondria, cytochrome c release from mitochondria and activation of caspase 9 and caspase 3. Moreover, a decreased phosphorylation of Akt, mTOR and ERK growth factor signaling kinases was evident and an increased phosphorylation of JNK was observed. Thus compound 1, and to some extent compound 2, hold potential as therapeutic agents that should be further explored for different tumor malignancies with specific emphasis on NSCLC and SCLC. were guided by MTT cell viability assay (see Cell viability assay below) and each fraction was tested for cell cytotoxicity in NSCLC U-1810 cells or in normal diploid fibroblasts WI-38 at 72 h of continuous exposure. The fraction that gave the best therapeutic window was chosen for further purification. Thus the crude extract was separated sequentially by different chromatographic methods starting with reversed phase vacuum flash chromatography using a gradient of solvents, from 100 % water through 100 % methanol and then 100 % ethyl acetate ( Supplementary Fig.   S1A ). The fraction 10 (90:10 mixture of methanol:water) obtained from the initial separation was further separated twice on a size exclusion Sephadex LH-20 column using chloroform:methanol (1:1 v/v) as mobile phase. In the last step of purification, the semi-pure fractions from the second Sephadex LH-20 column (fractions 8-11) were combined and separated on a reversed phase semipreparative YMC C-8 HPLC column with a mixture 40:51:9 of acetonitrile:methanol:water as the isocratic mobile phase. Several products were obtained from this last purification and pure compounds ( Supplementary Fig. S1B ) were tested for tumor specific toxicity. Two pure substances, (3S)-icos-4E-en-1-yn-3-ol (1) (t R 41.8 min, 70.1 mg, 95% purity) and (3S)-14-methyldocos-4E-en-1-yn-3-ol (2) (t R 67.0 min, 109.0 mg, 99% purity) were found to have the best therapeutic window and were therefore chosen for further analysis.
Materials and Methods

Collection and purification of extracts
The following characteristics were noted for compounds 1 and 2:
(3S)-icos-4E-en-1-yn-3-ol (1) 
Cell culture and treatments
C. vasculum parental extract (fraction 10) and compounds 1 and 2 were diluted in DMSO to make 10 mg/ml stock solutions which were kept at -20 °C and diluted in cell culture media prior to use.
Data on stability of compound 2 after long term storage in DMSO and in cell culture media after 72 h incubation time at concentrations used in experiments can be found in Supplementary Materials and Methods, sections Stability of compound 2 after long term storage and Stability of compound 2 in cell culture media.
The human SCLC U-1285 (20) and NSCLC U-1810 (21) were kind gifts from Uppsala University where they were established and characterized (22 with serum and antibiotics using Celprogen's human cardiomyocyte cell culture extra-cellular matrix pre-coated flasks (Celprogen Inc.). BJ-5ta were cultured in Dulbecco's modified Eagle's medium (HyClone) supplemented with 2 mM L-glutamine and 10 % FBS. BEAS-2B were grown in BEGM kit media (Lonza) and flasks were pre-coated with a mixture of 0.01mg/ml fibronectin (Sigma Aldrich), 0.03 mg/ml bovine collagen type I glutamine (Invitrogen) and 0.01 mg/mL bovine serum albumin (Sigma Aldrich) dissolved in BEBM (Lonza) to allow proper growth
Cell viability assay
The cytotoxicity induced by extracts or pure compounds was determined with the previously 
Mitochondrial permeability
The loss of mitochondrial membrane potential upon treatment with, DMSO, 3 µM of 1 or 2 for 24 h was assessed by staining the cells with tetramethylrhodamine ethyl ester perchlorate (MitoPT™ TMRE; Immunochemistry Technologies Bloomington, MN, USA) as previously been described (25) . Briefly, cells were treated with, DMSO, 3 µM of 1 or 2 for 24 h. As a positive control for depolarization of mitochondria the proton gradient uncoupling agent carbonyl cyanide 3- 
Analysis of proapoptotic conformational changes of Bak and Bax
During apoptosis the pro-apoptotic Bcl-2 family proteins Bax and Bak undergo N-terminal conformational changes leading to a pro-apoptotic state required for formation of pores in the mitochondria and subsequent cytochrome c release (26, 27) . To analyze N-terminal changes in Bak 
Cell cycle distribution
To assess cell cycle distribution, NSCLC U-1810 and WI-38 cells were treated with 1.3 M (BD Bioscience) and analyzed with ModFit LT (Verity Software House, Topsham, ME, USA).
Results
Isolation of anti-tumor extracts from Cribrochalina vasculum
Several compounds with antitumor activity have been isolated from marine derived organisms and some of them are already in clinical use (8) (9) (10) (11) . Here we set out to isolate and characterize antitumor compounds from the sponge C. vasculum with aim to reveal their antitumor mechanism of action. For that purpose material was collected and extracted as described in Material and
Methods. Resulting fractions were tested for antitumor activity against NSCLC U-1810 cells and for normal cell cytotoxicity using diploid fibroblasts WI-38 during 72 h continuous exposure.
Fraction 10 (named parental extract) from the C. vasculum extract induced significant cytotoxicity of NSCLC cells and almost completely inhibited cell growth at a concentration of 0.5 μg/ml while only minor cytotoxicity was evident in a normal diploid fibroblasts WI-38 up to a concentration of 25 μg/ml (Fig. 1A-B) . Given the observed NSCLC cell specific cytotoxicity we continued the purification of this fraction as outlined in Material and Methods and Supplementary Fig. S1A .
Chemical structure elucidation of Cribrochalina vasculum anti-tumor active fractions identifies (3S)-icos-4E-en-1-yn-3-ol (1) and (3S)-14-methyldocos-4E-en-1-yn-3-ol (2)
HPLC fractionation of the parental extract from C. vasculum ( Supplementary Fig. S1B ) yielded two known alkyl-4-en-1-yn-3-ol derivatives; 70.1 mg (0.035 % of sponge dry weight) of 95 % pure (3S)-icos-4E-en-1-yn-3-ol (1) and 109 mg (0.055 % of sponge dry weight) of 99 % pure (3S)-14-methyldocos-4E-en-1-yn-3-ol (2) (19) . The structures of 1 and 2 were confirmed by 1D and 2D Fig. S1C ) (19) . The absolute stereochemistry of 1 and 2 was determined by the Mosher method (29) since their optical rotations were small.
Structural analysis showed that compounds 1 and 2 are structurally related acetylenic alcohols both containing a C4-C5 trans double bond and the same absolute configuration of the hydroxyl group.
The structure determination also showed that the compounds differed in the length of their carbon chains and that 2 has a branched methyl substituent at position 14 ( Fig. 1C) .
Cribrochalina vasculum compounds 1 and 2 have tumor specific cytotoxicity
We next continued with the acetylene containing compounds 1 and 2 to reveal their antitumor effect and delineate their mechanism of action. Similar to the parental extract compounds 1 and 2 induced toxicity in NSCLC U-1810 cells but not in normal diploid fibroblasts WI-38 until 3 μM was used ( Fig. 2A) . A clear cytotoxicity was also evident when treating the NSCLC U-1810 cells with different concentrations of 1 and 2 for 72 h and examining cell viability with MTT assay (Fig. 2B) .
Thus, at concentration of 3 μM 1 reduced U-1810 cell viability for about 90 %, and 2 for 60 %.
Importantly, applying the same concentration of these compounds to WI-38 fibroblasts caused little or no cytoxicity suggesting a tumor selective window for these compounds. Thus the concentration of compound 1 and 2 needed to inhibit 50 % of cell viability (IC 50 ) was more than 10 times higher for WI-38 than for the U-1810 cell line (Supplementary Table S4 ). Next, the effect of 1 and 2 on cell cytotoxicity was examined also at 24 h and 48 h post treatment in U-1810 and WI-38 ( Supplementary Fig. S2 ). A clear time dependent increase in the cytotoxic effect of both compounds toward U-1810 cells was evident with a higher effect seen on the later time point. In contrast, neither 1 nor 2 impaired survival of diploid fibroblasts WI-38 at these earlier time points at doses up Fig. S2 and Supplementary Table S3 ).
Cribrochalina vasculum compounds 1 and 2 induce prominent cytotoxicity in SCLC but not in normal cells
Next we extended our analyses onto three small cell lung carcinoma cell lines (U-1285, H69 and H82) and two ovarian cell lines (SKOV-3 and A2780) (Fig. 2C, Supplementary Table S4 ). In order to asses normal cell toxicity human cardiomyocytes, human peripheral blood mononuclear cells (PBMC), foreskin fibroblasts immortalized with hTERT (BJ-5ta), bronchial epithelial cells (BEAS-2B) and hTERT immortalized retina epithelial cells (RPE-1) were used in the analyses (Fig. 2D , Supplementary Table S4) .
Of the SCLC cell lines, H82 showed the highest sensitivity towards compound 1 with an IC 50 of 1.1 µM and with an almost complete inhibition of cell survival at 1.5 µM (Fig. 2C, left panel) . The toxicity of compound 1 was slightly lower for U-1285 and H69, yet at 3 μM both these cell lines showed an 80 % decrease in cell viability and the corresponding IC 50 values were 1.6 and 2.2 μM, respectively (Supplementary Table S4 ). For compound 2 U-1285, H69 and H82 responded with about 80 % decrease in cell viability upon treatment with 3 µM concentration (Fig. 2C, right panel) .
IC 50 values were 1.8 µM for U-1285, 1.3 µM for H69 and 1.1 µM for H82 (Supplementary Table   S4 ). In ovarian carcinoma cells compound 1 caused a similar 80 % reduction in cell viability at 3 μM as seen in SCLC whereas for compound 2 both A2780 and SKOV-3 cells were less responsive (Fig. 2C) . Compound 1 reached IC 50 in A2780 at 1.8 μM and in SKOV-3 at 2.1 μM. Toxicity of compound 2 toward ovarian carcinoma was not so prominent, IC 50 
2 both demonstrate toxicity toward SCLC while for ovarian carcinoma compound 1 have a greater potency than compound 2.
Both compounds were tested against several normal cells. Treatment with 3 μM concentration of compound 1, which caused high cytotoxicity in all tumor cell lines tested, induced only 20 % reduction in cell viability in cardiomyocytes and BEAS-2B whereas in PBCM and BJ-5ta about 40 % cytotoxicity was evident (Fig. 2 D, left panel) . With the applied concentrations IC 50 value couldn't be reached for cardiomyocytes and BJ-5ta whereas for RPE-1 it was 6.6 μM, PBMC 7.8 μM and for BEAS-2B 12.9 μM (Supplementary Table S4 ). Compound 2 at 3 μM, a concentration that caused at least a 50% cell cytotoxicity in LC induced less than 15% cytotoxicity in cardiomyocytes, BJ-5ta, BEAS-2B and RPE-1 whereas in PBMC about a 35 % cytotoxic effect was evident (Fig. 2 D, right panel) . With compound 2 IC 50 value was reached only for PBCM and RPE-1 (8.5 μM for PBMC and 10.4 for RPE-1) (Supplementary Table S4 ).
In summary, the cytotoxic effect of compound 1 was significantly lower in all normal cells than in tumor cells whereas for compound 2 the tumor-selective effect was less prominent but evident in NSCLC and SCLC.
Cribrochalina vasculum compounds 1 and 2 induce apoptosis in NSCLC tumor cells but not in diploid fibroblasts
In order to further understand mechanism of action of these C. vasculum compounds, their effect on apoptosis induction was examined in NSCLC cells ( Supplementary Fig. S3A and Fig. 3A) .
Treatment of NSCLC U-1810 cells with either 1 or 2 (3 µM, 48 h) caused a prominent induction of apoptotic morphology of the cell nuclei whereas no major alteration was observed in diploid 
fibroblasts WI-38 upon treatment (Supplementary Fig. S3A ). Induction of apoptotic morphology in U-1810 cells was also quantified at 24-72 h post treatment with 1 or 2 (3 μM) (Fig. 3A) . Already 
Cribrochalina vasculum compound 1 induces G2 arrest in NSCLC but not in normal diploid fibroblasts
Loss of proliferation capacity and induction of cytotoxicity may also be attributed to inhibition of cell cycle progression. The effect of 1 on cell cycle distribution was therefore also evaluated (Fig.   3B ). NSCLC U-1810 or WI-38 fibroblasts were treated with different concentrations of 1 for 24 h.
In NSCLC U-1810 cells, treatment with 1 was found to induce a significant dose dependent increase in the number of cells arrested in the G2/M phase (Fig. 3B, left graph) . In contrast, cell cycle distribution of normal fibroblasts showed no alteration after treatment with compound 1 even at IC 50 concentration (Fig. 3B, right graph) . Thus the results showed that compound 1 clearly induces cell cycle arrest in G2/M in NSCLC tumor cells and this is a tumor-specific effect.
Cribrochalina vasculum compounds 1 and 2 induce mitochondrial depolarization, activate
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caspases-9 and 3 and cause PARP cleavage in NSCLC cells but not normal diploid fibroblasts
One important gateway to apoptosis is mitochondrial depolarization allowing cytochrome c to be released to the cytosol where it subsequently causes the pro-caspase-9 to be activated within the apoptosome complex. Caspase-9 in turn triggers cleavage of pro-caspase-3/7 into active proteases thereby giving rise to apoptotic morphology (30) . The effect of 1 and 2 on depolarization of mitochondria and release of cytochrome c was therefore examined. NSCLC U-1810 cells were treated with compounds 1 or 2 (3 μM) for 24 h and mitochondrial depolarization was examined with TMRE ( Fig. 4A) . Upon membrane depolarization, the potential of mitochondria is lost and the TMRE dye leaks into cytosol. Thus cells which have a decrease in TMRE staining represent cells with depolarized mitochondria and these cells were quantified. The mitochondrial uncoupler CCCP (50 μM, 45 min) was used as positive control showing that TMRE is capable of detecting alterations in mitochondrial potential (Fig. 4A) . Importantly, treatment with either compounds resulted in prominent mitochondrial depolarization (Fig. 4A) . Hence both compounds were capable of disrupting mitochondrial membrane potential.
Next the release of cytochrome c after treatment of NSCLC U-1810 cells with 1 and 2 (3 μM) for 16 h was analyzed by immunofluorescence staining (Fig. 4B) . A punctate staining pattern of cytochrome c indicative of mitochondrial localization was found in untreated cells whereas upon treatment with 1 or 2 diffuse staining pattern indicating release of cytochrome from mitochondria to cytosol was evident (Fig. 4B) .
In order to study whether depolarization of mitochondria and release of cytochrome c in response to 1 or 2 also resulted in the downstream activation of caspase 9/3 and subsequent apoptotic-associated cleavage of the caspase-3 substrate PARP-1 NSCLC U-1810 cells were treated with 1 or 2 for 24 h at a concentration that caused 50 % and 70 % of cell death respectively (Fig. 4C) . As can be seen in U-1810 cells both caspase-9 and caspase-3 were cleaved into active forms (35-37 and 15-17 kDa respectively) upon treatment with IC 50 or IC 70 of either compound. Treatment also resulted in clear cleavage of PARP-1 into the pro-apoptotic associated 89 kDa fragment confirming that these compounds indeed triggered an apoptotic response (Fig. 4C) . Normal fibroblasts WI-38 were used for comparison and treated with same concentrations as U-1810 cells. Importantly under these conditions no caspase-3 or PARP-1 cleavage was evident in normal WI-38 fibroblasts (Fig. 4C ).
However the lower pro-apoptotic activity of compounds observed in fibroblasts could be due to cell permeability rather than to a difference in actual mode of cell kill. In order to see if these compounds at all were able to induce apoptosis in these normal lung fibroblasts, concentrations that induced 50 % and 70 % cell kill at 24 h was applied. Even at these concentrations, no PARP-1 or caspases cleavage was observed in the fibroblast further demonstrating a NSCLC cell specific proapoptotic activity of these compounds (Fig. 4D) .
We also examined the kinetic of caspases and PARP-1 cleavage after treatment with 3 μM of 2 for 24, 48 and 72 h (Supplementary Fig. S3B ). In line with MTT and nuclear apoptotic morphology data, cleaved versus full-length caspase-3, caspase-9 and PARP-1 all clearly showed an increase over time in response to 2. Thus there is a clear NSCLC specific activation of apoptosis by both compounds. Activation of the Bcl-2 proteins Bak and Bax is one important gateway for the intrinsic mitochondrial pathway of apoptosis (26, 27) . The effect of compound 1 and 2 on Bax and Bak conformational changes associated with activation was therefore analyzed (Fig. 5A and 5B).
Cribrochalina vasculum compounds 1 and 2 trigger activation of Bak and
Indeed, treatment of NSCLC U-1810 cells with 3 μM of 1 or 2 resulted in prominent activation of Bak indicated by a shift of histogram peak to the right (Fig. 5A and 5B right). An activation of Bax was also observed after treatment of NSCLC U-1810 cells with either 3 μM of 1 or 2, yet less pronounced than for Bak ( Fig. 5A and 5B left). The total expression of Bax and Bak was also examined using conformation-independent antibodies in western blot (Fig. 5C ). However, no changes in their expression levels were evident upon treatment indicating that the observed Bak/Bax activation upon 1 or 2 relates to N-terminal conformational changes of these proteins.
The antiapoptotic Bcl-xL protein is reported to inhibit Bak/Bax complex formation and subsequent cytochrome c release (31) . The expression level of Bcl-xL was therefore examined after treatment with compound 1 or 2 and a clear decrease in Bcl-xL expression was evident after treatment with 1, while no change was observed after treatment with 2 ( Fig. 5C ). All in all, these results show that both 1 and 2 can activate the Bak/Bax rheostat in NSCLC cells which is in line with the observed depolarization of mitochondria, release of cytochrome c and activation of caspases via the intrinsic route after treatment with these compounds.
Bak and Bax complex formation is in part regulated by the BH3-only protein Bad which upon phosphorylation is sequestered by binding to 14-3-3 protein preventing its pro-apoptotic action (32) .
The effect of 1 or 2 in causing dephosphorylation of Bad was therefore examined. Indeed a decreased phosphorylation of Bad at Ser112 was clearly evident in response to treatment with 1 already at 16 h post treatment and still evident at 24 h in NSCLC U-1810 cells (Fig. 5C) response to treatment with 2 a moderate decrease in Bad phosphorylation was observed only at 24 h (Fig. 5C) . The observed alteration on Bad Ser112 in response to 1 was confirmed to be a result of altered signaling as no difference in total Bad protein expression was evident upon treatment (Fig.   5C ). Thus both compounds partly inhibit Bad phosphorylation indicating a putative pro-apoptotic action of Bad at mitochondria mediated apoptotic signaling in NSCLC cells.
Several growth factor signaling cascades are reported to control Bad phosphorylation thereby inhibiting its pro-apoptotic signaling capacity. The effect of 1 and 2 on the phosphorylation status of the Bad-regulating kinases Akt, Erk1/2 as well as on JNK, a kinase shown to promote apoptotic signaling (13, 33) was therefore evaluated. A decreased phosphorylation of Akt at both Ser473 and Thr308 was evident in NSCLC U-1810 cells after treatment with compound 1 or compound 2 with an earlier response seen with 1 (Fig. 5D) . Deactivation of mTOR was also evident after 1 as the phosphorylation on Ser2448 declined (Fig. 5D ). These data suggest that 1 and 2 impair PI3K/AKT pathway signaling and may in this way inhibit proliferation and survival of NSCLC cells. A decreased phosphorylation on Thr202/Tyr304 of ERK1/2 was also evident after treatment with both 1 and 2 again with a more prominent deactivation caused by compound 1 (Fig. 5D) . Hence a decreased pro-survival signaling via the MAPK ERK may also contribute to the observed cytotoxic activity of these two compounds in NSCLC cells. A sustained increase in JNK phosphorylation is reported to be critical for efficient induction of apoptotic signaling (33) . In line with this 1 caused increased phosphorylation of JNK1/JNK2 at 16 h and 24 h whereas in response to 2 a similar increase in phosphorylation was seen only at 24 h in these NSCLC cells. Thus this increased JNK phosphorylation may in part contribute to the observed apoptotic signaling in response to these compounds in this tumor type. 
Discussion
Here we analyzed the ability of C. vasculum derived metabolites to inhibit proliferation, induce cytotoxicity and trigger apoptotic signaling in NSCLC, SCLC and ovarian carcinoma. It has previously been shown that compounds isolated from this sponge can kill tumor cells of different origin albeit through unknown mechanism of action (19) . We show here that the two acetylenic compounds 1 and 2 as well as the parental mixture of these compounds from which they were separated, indeed cause tumor-specific cytotoxicity in NSCLC and SCLC. Importantly, we demonstrate that for both compounds this cytotoxicity is tumor specific, as all normal cells tested representing heart tissue, bronchial and retina epithelium, normal peripheral blood mononuclear cells, and foreskin or lung fibroblasts remained unaffected at concentrations that were toxic for NSCLC and SCLC. In ovarian carcinoma cells compound 1 but not compound 2 caused tumorspecific cell death. For compound 2 a cytotoxic effect was evident in NSCLC and SCLC whereas in ovarian carcinoma the difference compared to normal cells was less prominent.
With respect to NSCLC cytotoxicity we for the first time show that compounds from C. vasculum can induce a prominent apoptotic response whereas in normal fibroblasts no induction of apoptosis was seen after exposure to the same concentration of 1 or 2. Moreover no apoptosis was seen in normal fibroblasts even when concentrations that caused 50 % or 70 % cytotoxic response in cell viability assay were used. This indicates that the induction of apoptosis is a tumor selective path that might be a consequence of inhibition of cell survival signaling pathways which tumor but not normal cells rely upon on for protection against apoptotic cell death.
At an early stage of the intrinsic apoptotic pathway the pro-apoptotic Bcl-2 family proteins Bak and Bax are activated leading to permeabilization of the mitochondrial membrane, release of cytochrome c and activation of caspases within the apoptosome (34, 35) . We demonstrate that both 1 and 2 causes all these events in NSCLC cells. However, a more prominent activation of Bak over Bax was evident in these NSCLC cells. This is likely attributed to the basic signaling propensity of these NSCLC cells rather than specific action of these compounds to activation of Bak preferentially over Bax. This conclusion is based on the fact that we showed similar less pronounced activation of Bax also after treatment with other agents e.g. cisplatin and radiation in these NSCLC cells (25) .
When comparing 1 and 2 with respect to Bak activation and mitochondria-mediated apoptotic signaling, compound 2 was found to be less efficient. Compound 1 is, at the applied concentration 3 µM, more toxic toward U-1810 cells than is equimolar concentration of compound 2, likely explaining the more pronounced Bak and Bax activation and cytochrome c release. There was also the less efficient decrease of Bcl-xL protein expression upon exposure to 3 µM of compound 2. The presence of Bcl-xL could sequester Bak in an inactive state thereby preventing cytochrome c release and proper intrinsic route to caspase activation (34) . We demonstrate that both 1 and 2 subsequently trigger the cleavage and activation of caspase-9 and thereafter also caspase-3 showing that a full apoptotic signaling cascade is active in these NSCLC tumor cells but not in normal diploid fibroblasts. At their IC 50 
enabling Bak/Bax complex formation and cytochrome c release (36) . Bad function as an integrator of multiple growth factor signaling cascades including the PI3K/Akt and the Raf/MEK/ERK pathway which antagonize Bad function by phosphorylation causing its binding and sequestration to 14-3-3 protein (37, 38) . Akt inactivates Bad by phosphorylation at site Ser136 (39) while MAPK signaling cascade inactivates Bad protein at Ser112 and Ser155 (40) (41) (42) (43) . With respect to 1 and 2 Bad phosphorylation at Ser112 was markedly inhibited indicating a role for MAPK signaling pathway while the basal level of phosphorylation of the other sites i.e. in untreated cells were weak making effect of treatment unsecure (data not shown). Given this altered phosphorylation of Bad Ser112 by compound 1 and 2 we next examined how multiple growth and apoptosis promoting kinases in NSCLC cells were affected. A decrease in ERK phosphorylation was observed which is in line with the decrease in Bad protein phosphorylated at Ser112. Although results for inactivation of Bad protein at site Ser136 were inconclusive a major impairment of phosphorylation of Akt at Ser473 and Thr308 upon treatment with these compounds was evident. Deactivation of Akt is reported to cause activation of pro-apoptotic proteins, cause alterations in mitochondrial membrane potential, release of cytochrome c and caspase activation leading to activation of apoptosis (37, 43, 44) . Hence the impaired Akt phosphorylation upon treatment with these compounds fits well with observed apoptotic changes in these NSCLC cells.
We and others have linked NSCLC apoptotic response to a sustained JNK activation (33, (45) (46) (47) (48) (49) . In line with this and the observed apoptotic response, phosphorylation of JNK was increased by these C. vasculum derived compounds. All in all, our data clearly demonstrate that 1 and 2 inhibit 
controlled by growth factor receptors these results may indicate that a common growth factor receptor instrumental in controlling their activity could indeed be a target of C. vasculum compounds. Further studies are however needed to reveal if that is the case. We observed that Bak and Bax activation, cytochrome c release, downregulation of Bcl-xL, Bad, Akt, mTor, p43/p44MAPK (ERK1/2), JNK1/JNK2 phosphorylation alteration were delayed or less affected by 2 than by 1 in these NSCLC cells when used at equimolar concentrations. Yet given that 1 has a higher toxicity than 2 one cannot rule out that this is the underlying effect. Therefore at this point we can only say that both compounds are capable of inducing apoptosis in tumor cells.
We show that 1 is also capable of enhancing cytotoxicity through induction of G2/M cell cycle Hence further research is required in order to put an answer to these issues.
In conclusion our data reveal that 1 isolated from marine sponge C. vasculum causes tumor specific cell death in NSCLC, SCLC and ovarian carcinoma. For compound 2 we found such an activity to be evident in NSCLC and SCLC but not in ovarian carcinoma. Our findings are summarized in Fig.   6 . We show that in NSCLC these compounds trigger a prominent response of the intrinsic apoptotic pathway (activation of Bak/Bax, decreased phosphorylation of Bad, depolarization of mitochondria, release of cytochrome c and activation of caspase-9 and caspase-3) and cell cycle arrest in G2/M phase with a concomitant inhibition of both Akt and ERK/MAPK growth promoting pathways.
Moreover, we show that in NSCLC these compounds trigger a sustained JNK activation which may contribute to the observed pro-apoptotic capacity. Taken together our results therefore implicate that one or several growth factor receptors could be target of 1 and 2 either directly or indirectly and in this way trigger cell death through the intrinsic apoptotic pathway and cell cycle arrest. Further studies of the effects of compounds on growth factor receptors are therefore warranted in order to reveal mechanism of action, develop these compounds into suitable pharmacological leads as well as to understand their role in treatment of NSCLC and SCLC but also other tumor malignancies.
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